EFPIA Opens Up To Company Membership
The European Federation of Pharmaceutical Industries' Associations hasannounced a fundamental restructuring. EFPIA membership is to be extended from the national drug industry associations of 16 European countries to also include research-based companies.
To be accepted, companies (which will be accepted as full members during the EFPIA general assembly in November) will have to do significant research, develop and manufacture in Europe human medicinal products and belong to the EFPIA member association in most of the countries where it operates.
The "new" EFPIA says its mission is to encourage favorable policy conditions to enable the industry in Europe to contribute to scientific progress worldwide, and to consolidate the industry's competitiveness in order to optimize the development of medicinal products and advanced health care benefits.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze